## **Answering Reviewers**

Dear editor and Reviewers:

Thank you for your letter and the reviewers' comments concerning our manuscript entitled "Prognostic role of RFWD3 and immune cell infiltration in hepatocellular carcinoma" (Manuscript number: 80909). These comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. We have revised and resubmit the revised manuscript. The main corrections in the paper and the responds to the reviewer's comments are as flowing:

## **Responds to the reviewer's comments:**

## Reviewer 1

 The authors appreciated the reported unique view in probing into the prognostic implication of RFWD3 in HCC. They explored the correlation between RFWD3 expression and infiltration level of 24 immune cells. However, I think the research is not innovative enough. And the author only used database data for analysis, and did not verify in patient samples.


**Author response and action taken:** Our studyindicated that the research performed by Liang et al. is worthy of attention and that our discover may be provide supplementary information to their study, which can make the study more significant. Liang et al.

## **Reviewer 2**

2. Excellent work. It should be a full paper. Considering that half of the patients were

classified as stage I (BCLC?), I wonder if RFWD3 expression differs among stages.

**Author response and action taken:** First of all, thank you very much for your recognition of our work. RFWD3 was not significantly differentially expressed in different stages of hepatocellular carcinoma.



Thank you very much for your careful and meticulous work.

We appreciate for Editors/Reviewers' warm work earnestly, and hope that the correction will meet with approval.

Once again, thank you very much for your comments and suggestions.

Yours sincerely,

Fang Zhang